Aclaris Therapeutics (ACRS) News Today → Don’t buy a single NVIDIA share before you see this... (From Behind the Markets) (Ad) Free ACRS Stock Alerts $1.03 -0.02 (-1.90%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 1:22 AM | americanbankingnews.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 18.2% in MayMay 31 at 1:21 AM | marketbeat.comShort Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Drops By 18.2%Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the target of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 4,870,000 shares, a drop of 18.2% from the April 30th total of 5,950,000 shares. Based on an average trading volume of 899,100 shares, the days-to-cover ratio is presently 5.4 days.May 28, 2024 | americanbankingnews.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Hold" from AnalystsMay 28, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Hold" from BrokeragesShares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have earned a consensus rating of "Hold" from the seven brokerages that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to thMay 22, 2024 | americanbankingnews.comAclaris Therapeutics (NASDAQ:ACRS) Share Price Passes Below Fifty Day Moving Average of $1.21May 22, 2024 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Stock Passes Below Fifty Day Moving Average of $1.21Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Crosses Below 50 Day Moving Average of $1.21May 14, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 19.2% in AprilAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 5,950,000 shares, a growth of 19.2% from the April 15th total of 4,990,000 shares. Based on an average daily volume of 1,070,000 shares, the short-interest ratio is currently 5.6 days.May 11, 2024 | marketbeat.comMonaco Asset Management SAM Invests $1.03 Million in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Monaco Asset Management SAM bought a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 979,399 shares of the biotechnology company's stock, valued at approximately $1,028,000. Monaco AssetMay 10, 2024 | finance.yahoo.comEarnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their EstimatesMay 10, 2024 | marketbeat.comLeerink Partnrs Equities Analysts Raise Earnings Estimates for Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities researchers at Leerink Partnrs boosted their Q2 2024 earnings per share estimates for Aclaris Therapeutics in a research note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now anticipates that the biotMay 8, 2024 | finance.yahoo.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | businesswire.comAmerican Clinical Research Services Announces Strategic Acquisition of ElixiaMay 8, 2024 | finance.yahoo.comAclaris Therapeutics Inc (ACRS) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...May 7, 2024 | msn.comCrocs (CROX) Q1 2024 Earnings Call TranscriptMay 7, 2024 | sfgate.comAclaris: Q1 Earnings SnapshotMay 7, 2024 | globenewswire.comAclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateMay 7, 2024 | markets.businessinsider.comHere's what to expect from Aclaris Therapeutics's earnings reportMay 1, 2024 | marketbeat.comAclaris Therapeutics (ACRS) to Release Earnings on TuesdayAclaris Therapeutics (NASDAQ:ACRS) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=592103)April 30, 2024 | finance.yahoo.comAclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate UpdateApril 27, 2024 | money.usnews.comAclaris Therapeutics IncApril 24, 2024 | marketbeat.comBML Capital Management LLC Invests $686,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)BML Capital Management LLC bought a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 653,107 shares of the bioApril 11, 2024 | finance.yahoo.comFavourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired StockMarch 25, 2024 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by StockNews.comStockNews.com upgraded Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday.March 16, 2024 | finance.yahoo.comACRS Apr 2024 1.000 callMarch 8, 2024 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Lowered to "Sell" at StockNews.comStockNews.com lowered Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday.March 7, 2024 | marketbeat.comHC Wainwright Analysts Reduce Earnings Estimates for Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Stock analysts at HC Wainwright decreased their Q3 2024 earnings per share estimates for shares of Aclaris Therapeutics in a research note issued to investors on Monday, March 4th. HC Wainwright analyst R. Selvaraju now expects that the bioMarch 6, 2024 | marketbeat.comHC Wainwright Weighs in on Aclaris Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ACRS)Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Research analysts at HC Wainwright issued their FY2025 earnings per share estimates for Aclaris Therapeutics in a research note issued on Monday, March 4th. HC Wainwright analyst R. Selvaraju anticipates that the biotechnology company willMarch 4, 2024 | markets.businessinsider.comAclaris Therapeutics: Cautious Hold Rating Amid Financial Stability and Pipeline PotentialMarch 4, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest UpdateAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) saw a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 5,830,000 shares, a drop of 7.9% from the January 31st total of 6,330,000 shares. Based on an average trading volume of 2,480,000 shares, the days-to-cover ratio is presently 2.4 days.March 1, 2024 | markets.businessinsider.comAclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical SetbacksMarch 1, 2024 | marketbeat.comAclaris Therapeutics, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.31) Per Share (NASDAQ:ACRS)Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Analysts at William Blair raised their Q1 2024 earnings estimates for Aclaris Therapeutics in a note issued to investors on Tuesday, February 27th. William Blair analyst T. Lugo now expects that the biotechnology company will post earningsMarch 1, 2024 | marketbeat.comDeutsche Bank AG Sells 932,311 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Deutsche Bank AG decreased its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 85.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 154,309 shares of the biotechnology compFebruary 29, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Aclaris Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:ACRS)Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Research analysts at William Blair issued their Q1 2025 EPS estimates for shares of Aclaris Therapeutics in a research note issued to investors on Tuesday, February 27th. William Blair analyst T. Lugo anticipates that the biotechnology compFebruary 29, 2024 | finance.yahoo.comAnalysts Have Just Cut Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Revenue Estimates By 51%February 27, 2024 | msn.comAclaris Therapeutics GAAP EPS of -$0.02 beats by $0.31, revenue of $17.6M beats by $12.55MFebruary 27, 2024 | globenewswire.comAclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateFebruary 20, 2024 | finance.yahoo.comPacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 ReleaseFebruary 20, 2024 | marketbeat.comAclaris Therapeutics (ACRS) Scheduled to Post Earnings on WednesdayAclaris Therapeutics (NASDAQ:ACRS) will be releasing earnings on Wednesday, February 21, Yahoo Finance reports.February 15, 2024 | finance.yahoo.comWill Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should KnowFebruary 7, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) to Post FY2023 Earnings of ($1.63) Per Share, Leerink Partnrs ForecastsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Leerink Partnrs increased their FY2023 earnings per share estimates for Aclaris Therapeutics in a research note issued on Monday, February 5th. Leerink Partnrs analyst T. Smith now expects that the biotechnology company will post earnings oFebruary 6, 2024 | msn.comAclaris Therapeutics Executive Team Undergoes Major ChangesFebruary 6, 2024 | marketbeat.comAnalysts Set Expectations for Aclaris Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ACRS)Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities research analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for shares of Aclaris Therapeutics in a report issued on Monday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the biotechnology companyJanuary 22, 2024 | msn.comHW Wainwright cuts Aclaris to neutral, cites underwhelming study dataJanuary 16, 2024 | msn.comWhy Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?January 16, 2024 | bizjournals.comAclaris moves on from CEO and begins strategic review following recent setbacksJanuary 11, 2024 | msn.comBTIG Downgrades Aclaris Therapeutics (ACRS)January 11, 2024 | markets.businessinsider.comThe Analyst Landscape: 4 Takes On Aclaris TherapeuticsJanuary 11, 2024 | realmoney.thestreet.comJefferies gets more bearish on Aclaris Therapeutics, downgrades sharesJanuary 10, 2024 | msn.comAclaris downgraded at Jefferies despite mid-stage win for eczema therapyJanuary 10, 2024 | markets.businessinsider.comAnalyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Kiss of death from Joe Biden (Ad)I did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care. I have uncovered a bombshell that changes everything… and threatens everything. ACRS Media Mentions By Week ACRS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRS News Sentiment▼1.010.79▲Average Medical News Sentiment ACRS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRS Articles This Week▼62▲ACRS Articles Average Week Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Oncolytics Biotech News Today Barinthus Biotherapeutics News Today Tiziana Life Sciences News Today Hookipa Pharma News Today Vaccitech News Today SELLAS Life Sciences Group News Today Spero Therapeutics News Today Aileron Therapeutics News Today Anixa Biosciences News Today Chimerix News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRS) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
